Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in Eye Care

Journal Scan / Research · May 05, 2022

The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on IOP

Ophthalmology

 

 Save  Recommend
 Share

Additional Info

Ophthalmology
The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis
Ophthalmology 2022 May 01;129(5)498-508, K Nanji, GS Sarohia, K Kennedy, T Ceyhan, T McKechnie, M Phillips, T Devji, L Thabane, P Kaiser, D Sarraf, SJ Garg, S Sivaprasad, CC Wykoff, SJ Bakri, T Sheidow, M Bhandari, V Chaudhary

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated